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Following arterial occlusion, blood vessels respond by forming a new network of functional 
capillaries (angiogenesis), by re-organizing pre-existing capillaries through the recruitment of 
smooth muscle cells to generate new arteries (arteriogenesis) and by growing and 
remodeling pre-existing collateral arterioles into physiologically relevant arteries (collateral 
development). All these processes result in the recovery of organ perfusion. The importance 
of endoglin in post-occlusion reperfusion is sustained by several observations: i) endoglin 
expression is increased in vessels showing active angiogenesis/remodeling; ii) genetic 
endoglin haploinsufficiency in humans causes deficient angiogenesis; and iii) the reduction of 
endoglin expression by gene disruption or the administration of endoglin-neutralizing 
antibodies reduces angiogenesis and revascularization. However, the precise role of endoglin 
in the several processes associated with revascularization has not been completely elucidated 
and, in some cases, the function ascribed to endoglin by different authors is controversial. The 
purpose of this review is to organize in a critical way the information available for the role of 
endoglin in several phenomena (angiogenesis, arteriogenesis, and collateral development) 
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Adult mammals have developed a set of physiological mechanisms that regulate the supply of 
nutrients and oxygen to tissues according to their requirements. When an organ changes its 
metabolism in an acute way, blood flow along arteries, arterioles and capillaries can be 
controlled, depending on the metabolic requirements of this organ, to maintain a balance 
between the oxygen and nutrient requirements, the removal of waste products, and the blood 
flow supply. Acute blood flow regulation is managed by adjusting the contraction or 
relaxation of smooth muscle fibers in the walls of arterioles. However, when an organ or 
tissue suffers a long-term lack of adequate blood supply (ischemia), some other mechanisms 
are activated to correct this deficiency. Ischemia comprises not only an insufficiency of oxygen 
but also a reduced availability of nutrients and an inadequate removal of metabolites. The 
response to ischemic situations includes a coordinated set of processes: i) "de novo" 
formation of a network of functional capillaries by budding off of endothelial cells (ECs) from 
the walls of preexisting capillaries (angiogenesis), ii) transformation of pre-existing 
capillaries in conductance arteries and veins (arteriogenesis) and iii) growth and remodeling 
of pre-existing low flow collateral arterioles that connect main arteries to physiologically 
relevant arteries (collateral development) [1]. This last process is also called arteriogenesis 
by several authors [2]. The contribution of each of these processes to revascularization after 
arterial obstruction depends on the organ perfused and the velocity of the arterial occlusion 
(acute or progressive).  
During angiogenesis, preexisting ECs perform highly orchestrated morphogenic events that 
include basement membrane degradation, EC sprouting and branching, vessel lumen 
formation, vessel anastomosis and maturation, and mural cell recruitment, resulting in a new 
vascular network that provides blood to the hypoxic tissue [3, 4].  
A different strategy to generate adequate blood flow for the metabolic demand of the tissue 
after ischemia is vascular remodeling, including arteriogenesis and collateral growth or 
development. Despite the considerable terminological confusion that has even stimulated 
the writing of specific reviews regarding the nomenclature used [5], there is an unambiguous 
difference between arteriogenesis and collateral growth: arteriogenesis is the appearance of 
new arteriolar structures from preexisting capillaries, whereas collateral growth is the 
development and remodeling (anatomic increase in lumen area and wall thickness) of 
preexisting arterio-arterial anastomoses to form functional conducting arteries that 
significantly contribute to tissue perfusion [1]. During the arteriogenesis process, the 
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persistent increased oxygen demand by the ischemic organ induces arteriolar vasodilatation 
and increased blood flow in downstream vessels. Consequently, increased shear stress 
induces the maturation of capillaries towards arteries. In this manner, preexisting EC 
channels become covered by pericytes and vascular smooth muscle cells (VSMCs), which 
provide stability and control of the perfusion of newly formed arteries. During the collateral 
growth process, upon occlusion of an artery, the blood flow is redirected into preexisting 
arterio-arterial anastomoses (collateral vessels) due to the sudden pressure gradient between 
the high pressure in pre-occlusive regions and the low pressure in the post-occlusive areas 
that are connected by these collaterals. Thus, these arteries are exposed to increased 
mechanical forces such as pulsatile fluid shear stress [6]. As a consequence of the increased 
shear stress, the endothelium of the collateral arteriolar connections is activated, resulting in 
increased release of nitric oxide (NO), vascular endothelial growth factor (VEGF) and 
monocyte-attracting proteins such as monocyte chemoattractant protein-1 (MCP-1), as well 
as an upregulation of adhesion molecules (VCAM-1, ICAM-1, among others). Upon adherence 
and extravasation, monocytes promote vascular wall development by supplying growth 
factors and cytokines such as granulocyte-monocyte colony-stimulating factor (GM-CSF) or 
transforming growth factor-β1 (TGF-β1) [7–10]. All these mechanisms are described in detail 
later in this review. 
It has been reported that angiogenic processes take place mainly in the microvascular 
circulation, whereas the macrovascular endothelium mainly drives arteriogenesis and 
vascular remodeling. While both have common signaling routes and responses, cell-by-cell 
analysis shows differential gene expression patterns, suggesting the presence of different 
highly regulated processes [11]. 
Inadequate angiogenesis or arteriogenesis is responsible for several types of diseases (4-6): 
(i) Pathologies with excessive angiogenesis/vascular remodeling including hemangiomas, 
psoriasis, Kaposi's sarcoma, ocular neovascularization and retinopathy of prematurity, 
rheumatoid arthritis, endometriosis, atherosclerosis and, the most studied, tumor growth and 
metastasis; (ii) Pathologies with poor angiogenesis/vascular remodeling, which include 
myocardial ischemia, peripheral limb ischemia, cerebral ischemia, delayed wound healing and 
impaired ulcer healing; and (iii) Pathologies with defective angiogenesis/vascular remodeling, 
in which the number of formed vessels is normal, but their structure and cellular composition 
is abnormal, such as arteriovenous malformations, telangiectasias or even tumor vessels, in 
which angiogenesis is not only excessive but also defective. 
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As described above, ECs play a main role in both angiogenic and vascular remodeling 
processes, and many endothelium-related proteins and soluble factors are also involved in 
this process. In this context, endoglin (CD105), a co-receptor for several members of the TGF-
β family expressed mainly in ECs, has been shown to be essential for the correct course of 
angiogenic processes [12–14]. Endoglin expression is enhanced in endothelium during active 
angiogenesis, both in non-tumor and tumor tissues [15, 16], and endoglin expression 
specifically rises at the angiogenic edge where vessel sprouting occurs [17]. A lack of endoglin 
or defective endoglin function results in impaired angiogenesis, revascularization and tumor 
growth [18–22]. Moreover, endoglin is used as a biomarker for a poor prognosis in several 
cancers [23, 24], and endoglin-neutralizing antibodies have demonstrated antitumor 
angiogenesis properties, as recently reviewed [25, 26]. Additionally, a new role for endoglin in 
integrin-mediated angiogenic and vascular remodeling processes can be suggested in light of 
the recent discovery that endoglin is involved in the regulation of leukocyte recruitment [27] 
and in integrin-dependent cell adhesion processes, including pericyte attachment to ECs [28]. 
These data suggest that endoglin is a potential target for the regulation of defective or 
excessive angiogenesis. However, the mechanisms by which endoglin contributes to 
vascularization mechanisms have not been fully elucidated. 
The purpose of the present review is to organize in a critical way the information available 
regarding the role of endoglin in the different phenomena associated with post-ischemic 




Capillaries and small vessels are the major protagonists of angiogenesis. The vascular wall in 
these vessels is composed of the vascular endothelium and mural cells. The vascular 
endothelium is a cell monolayer that lines all blood-contacting surfaces in the circulatory 
system. Its strategic location allows the endothelium to detect changes in oxygen and nutrient 
availability, blood flow, shear stress or arterial pressure and to initiate vascular processes in 
response to these changes. Thus, following several stimuli, the endothelium produces a wide 
variety of mediators that communicate events inside the vessel lumen to mural cells [7]. 
The term mural cell refers generally to VSMCs and pericytes, both of which are involved in the 
formation of normal vasculature and are responsive to VEGF [29]. Pericytes are embedded in 
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the basement membrane of the smallest blood vessels, where they communicate with ECs by 
means of both direct physical contact and paracrine signaling and are responsible for vessel 
stabilization and maturation [30].  
 
Hypoxia as the main angiogenic stimulus: HIF-1α and VEGF as principal mediators 
Impairment of the blood supply to an organ leads to the generation of a hypoxic 
microenvironment because the oxygen supply is lower than the oxygen demand of this organ. 
In the hypoxic microenvironment, the cellular response to low oxygen bioavailability involves 
the accumulation of the hypoxia–inducible transcription factor 1 (HIF-1). Under normoxic 
conditions, the cytoplasmic HIF-1 alpha subunit (HIF-1α) is ubiquitinated by the von Hippel-
Lindau factor (pVHL) ubiquitin-ligase domain and subsequently degraded in the proteasome. 
HIF-1α has an oxygen-dependent degradation domain (ODD), which is hydroxylated by 
enzymes that are directly dependent on O2 as a cofactor. The decreased O2 bioavailability 
during hypoxia blocks HIF-1α hydroxylation and thus pVHL binding to HIF-1α, which will no 
longer be degraded in the proteasome. Thus, HIF-1α accumulates in the cytosol, translocates 
into the nucleus and binds to the HIF-1 subunit to form the active transcription factor [31] 
(Figure 1a). This transcription factor induces VEGF gene expression, a potent proangiogenic 
cytokine that induces EC differentiation, triggering the sprouting of ECs to form new vessels 
(Figure 1b). The VEGF gene has a hypoxia response element (HRE) within its promoter and an 
enhancer sequence to which HIF-1 binds once inside the nucleus and induces VEGF 
expression after hypoxia [32, 33]. Thus, HIF-1 belongs to the transcriptional complex that 
regulates hypoxia-induced VEGF expression, together with other transcription factors 
identified described later [34].   
Fibroblast growth factors (FGFs), particularly FGF1 and FGF2, are also potent proangiogenic 
factors. FGFs stimulate new blood vessel formation by driving EC proliferation and migration 
and also promoting extracellular matrix degradation and pericyte recruitment [35]. Both FGF 
and VEGF families act synergistically to promote neovascularization because FGF2 
upregulates the expression of VEGFR and VEGF in ECs. VEGF upregulates the expression of 




Sprouting and anastomosis  
In response to angiogenic stimuli, ECs change their phenotype and bud to form a branch 
sprout in a process called sprouting. Vessel exposure to proangiogenic signals such as VEGF 
leads to the acquisition by a fraction of ECs of the commonly known tip cell phenotype, which 
is characterized by the formation of specialized structures, such as filopodia with migratory 
capacity and is responsible for sprout guidance. Neighboring cells remain attached to this tip 
cell and undergo proliferation behind it to form a stalk, in a precisely regulated molecular 
process in which the Notch/Dll4 pathway plays a prominent role. Stalk cells are also 
responsible for forming a lumen connected to the lumen of the parent vessel [37–40]. Growth 
of the sprout towards the stimulus requires EC migration, invasiveness and proliferation. Tip 
cells respond to a gradient of chemokines, mainly VEGF-A, which determine its migration 
direction (Figure 2a). It is unclear whether tip cells migrate before stalk cell proliferation and 
formation of the tube, or whether stalk cell proliferation push the tip cells forward [37]. 
Sprouting also requires the local degradation and new synthesis of the surrounding basement 
membrane, mediated by matrix metalloproteinases such as the MT1-MMP family. ECs 
themselves mediate extracellular matrix (ECM) cleavage, which entails soluble factor release, 
during the angiogenic response [3]. 
Endothelial progenitor cells (EPCs) differentiated from hemangioblasts (multipotent 
precursor cells that can differentiate into both hematopoietic and ECs) were believed to be 
involved only in vasculogenesis, and embryonic mesodermal cells in situ differentiate into 
angioblasts that form the primary capillary plexus of the embryo. However, they also play a 
role in vascularization in the adult [41, 42] by both generating a sprout on their own – 
‘postnatal or adult vasculogenesis’ – or stimulating mature ECs to undergo sprouting [37, 43]. 
The involvement of EPCs in neovascularization has been shown to be essential for ischemic 
disease recovery or in vascularization after stroke [44–46]. 
After sprout elongation towards the angiogenic stimulus, tip cells can meet other tip cells 
belonging to other sprouts of different origin. Anastomosis of both sprouts leads to the 
formation of an entire new capillary that can undergo maturation [47, 48]. 
 
Endothelial cells drive and mural cells polish angiogenesis  
Mural cells have been demonstrated to be essential for angiogenesis, the structural integrity 
of the microvasculature and blood flow regulation, as they contribute to the formation 
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of mature capillaries and pre-capillary arterioles. The interaction and interplay between ECs 
and mural cells plays a pivotal role in vascular biology, including the control of lumen and 
tube formation, neovessel stability and the migration, proliferation, differentiation and 
survival of both cell types. In this regard, the recruitment of pericytes and VSMCs along the 
endothelial tube networks represents a critical event controlling capillary remodeling, 
maturation and stabilization [49] (Figure 3). Furthermore, mural cell and EC co-assembly 
leads to vascular basement membrane deposition and tube stabilization in 3D matrices [50]. 
Several adhesion receptors and signaling pathways have been reported to be involved in the 
interaction between ECs and mural cells. Growing vascular sprouts generate a concentration 
gradient of platelet-derived growth factor-B (PDGF-B). High levels of PDGF-B produced by tip 
cells promote the recruitment of mural cells expressing the PDGF receptor β (PDGFR-β), 
stabilizing the growing vessels [37, 51]. In addition, co-cultured VSMCs enhance EC adhesion 
through activation of paxillin and ERK [52]. Moreover, pericyte-EC interactions depend on 
numerous direct contacts such as peg-socket contacts and adhesion plaques, which involve 
vascular endothelial cadherin (VE-cadherin) trafficking [53].  
Mural and endothelial cells express several members of the integrin adhesion family of 
proteins, which are involved in the cell-cell and cell-matrix adhesion processes required for 
angiogenesis and vessel maturation [54]. A multiprotein complex involving integrin αvβ8 
regulates vascular stability, angiogenesis and EC proliferation in the developing embryo [55]. 
In addition, β1 integrin family members, including the fibronectin receptor α5β1, are major 
determinants of the mural cell phenotype, controlling mural cell adhesion and spreading and 
blood vessel wall stability [56]. Interestingly, integrins can be activated by proangiogenic 
chemokines such as CXCL12, triggering EC and leukocyte spreading and migration in an 
integrin-dependent manner [27, 57–59]. Moreover, CXCL12, which is upregulated by hypoxia 
[60], increases PDGF-B expression by ECs and promotes the differentiation and recruitment of 
pericytes and vascular remodeling [61], as well as myogenic differentiation [62]. Furthermore, 
CXCL12-induced expression of PDGF-B is in turn a potent activator of integrins [63]. However, 
despite the emerging relevant role of integrins as cell adhesion receptors in vascular biology 





Vascular remodeling is an active process of structural alterations and arrangement of blood 
vessels that involves cell differentiation, proliferation, migration, death and ECM production. 
As described above, vascular remodeling after artery occlusion is a major process involved in 
organ reperfusion and includes at least two different processes that are often confused with 
one another: collateral growth and arteriogenesis.  
Collateral growth is a vessel remodeling process with major importance for the restoration of 
organ perfusion after an arterial occlusion. It consists of the remodeling of pre-existing 
arterio-arterial anastomosis with a very low flow to produce high capacity conductance 
arteries that provide most of the needs of the ischemic tissue for oxygen and nutrients. These 
arteries enlarge after femoral occlusion, and it is widely accepted that the number of pre-
existing collaterals does not increase after arterial occlusion, not even after maximal 
stimulation by increased shear stress [2]. Moreover, some authors postulate that collaterals 
can provide sufficient blood flow to substantially diminish ischemic tissue injury after sudden 
arterial obstruction [67, 68] and that post-ischemic reperfusion can be achieved without any 
other associated processes such as angiogenesis or arteriogenesis [69]. 
However, long-term ischemia produces necrosis and vascular network regression. 
Consequently, even if blood flow is restored by collateral growth, a new expanded vascular 
network is required for the appropriate delivery of blood to all cells of these tissues. This 
phenomena, which is also called neovascularization, is often considered synonymous with 
angiogenesis, but it involves much more extensive sequences of temporally controlled 
vascular processes, beginning with angiogenesis and the ensuing formation of a new, larger 
functional circulatory network. During this process, neovessels remodel via vascular cell 
differentiation and incorporation of perivascular cells into the newly formed vessel walls, 
resulting in the appropriate density and distribution of arterioles, venules and capillaries. 
Finally, the new vascular network matures and remodels into a more efficient perfusion 
circuit that meets the tissue perfusion needs and functions. This process of transformation 
from a capillary into a mature artery is called arteriogenesis, and this is the term that we will 
use in this review. It should be noted that the term arteriogenesis is also used by many 
researchers to describe collateral growth [69]. 
The mechanisms and signals for mural cell recruitment to newly formed vessels have been 
described in a previous section. However, vascular wall development is dependent on other 
mechanisms that are common to arteriogenesis and collateral growth. The major inducer of 
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this process is shear stress. In the first scenario, transmural pressure-induced stretch 
secondary to intravascular blood pressure contributes to vessel wall muscularization in 
arteriogenesis [70]. Moreover, it has been demonstrated that collateral growth is not 
stimulated by ischemia but by deformation of the endothelial cells through increased pulsatile 
fluid shear stress (FSS) caused by the pressure gradient created between the high pressure in 
pre-occlusive regions and the low pressure in post-occlusive areas connected by these 
collaterals [6, 71]. ECs exposed to prolonged laminar shear stress undergo configurational 
changes in surface adhesion receptors (including selectins and integrins). These changes 
result in cytoskeletal remodeling and subsequent activation of signal transduction pathways, 
ultimately leading to an anti-apoptotic state and increased release of the vasodilator NO by 
activation and expression of all NOS isoforms (eNOS, iNOS and nNOS) [72, 73]. NO plays a 
major role in stimulating arteriogenesis, as its inhibition markedly reduces the effects of 
increased FSS, whereas all NOS isoforms are significantly upregulated both at the 
transcriptional and at the translational level [73]. Deletion of both eNOS and iNOS leads to 
complete loss of collateral vessel remodeling upon femoral arterial occlusion [74, 75]. 
Moreover, increased shear stress mediates endothelium quiescence by inhibiting EC 
proliferation and promotes pericyte recruitment [76]. Elevations in shear stress also lead to 
the production of MCP-1 in the endothelium and the smooth muscle layer, which leads to a 
cascade inflammatory response with infiltrating leukocyte populations. MCP-1 attracts 
monocytes and T-cells into the vessels during remodeling, a process that is favored by the 
marked increase in the expression of adhesion molecules on the endothelial surface of 
growing vessels. The monocytes that have accumulated into the collateral walls transform 
into macrophages, and resident macrophages become also activated. Mononuclear and 
activated VSMCs produce proteases and growth factors to digest the extracellular scaffold, 
allowing VSMC motility and providing space for the new cells. In addition to its participation 
in the digestion of the extracellular scaffold, monocytes produce paracrine growth factors 
necessary for the regeneration of arterial tissue [77] (Figure 2b). The major role of monocytes 
in arteriogenesis has been demonstrated by many experimental approaches, showing that the 
administration of MCP-1 or other substances favoring monocyte recruitment, or over-
transfusion with monocytes, markedly stimulated collateral growth, whereas reduction of the 
blood monocyte count or deletion of the genes for MCP-1 or for the MCP-1 receptor (CCR2) 
was associated with markedly reduced collateral growth [2]. 
In addition to monocytes, other leukocytes also contribute to arteriogenesis, mainly T-
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lymphocytes and NK-cells [78, 79]. Furthermore, EPCs have also been reported to be 
recruited by growing vessels, changing their phenotype into ECs or VSMCs [80, 81]. 
ECs play also an important role in mural cell recruitment, but their role has been described in 
a previous section (Endothelial cells drive and mural cells polish angiogenesis). 
 
 
A KEY ROLE OF ENDOGLIN IN ANGIOGENESIS AND VASCULAR REMODELING 
What is endoglin?  
Endoglin (Eng, CD105) is a type I homodimeric membrane glycoprotein that acts as an 
auxiliary receptor in the receptor complex for several members of the TGF-β family of 
cytokines. The TGF-β family comprises not only TGF-β isoforms but also bone morphogenetic 
proteins (BMPs), activins, inhibins, growth and differentiation factors (GDFs), among others. 
Endoglin interacts with type I and type II TGF-β receptors (TβRI and TβRII, respectively) to 
form the signaling TGF-β receptor complex [82]. Endoglin is highly involved in endothelium 
function and vascular homeostasis; it plays a major role in angiogenesis [83]. 
The predominant full-length endoglin isoform, L-endoglin, is formed by two 90-kDa 
monomers that are linked to one another by disulfide bonds. Structurally, the extracellular 
region of endoglin contains two distinct domains: (i) a zona pellucida (ZP) juxtamembrane 
domain that in human endoglin displays the prototypic Arg-Gly-Asp (RGD) motif involved in 
integrin-based interactions [84, 85], which has a mouse homologous sequence, TDD [27]; and 
(ii) the NH2-terminal orphan domain involved in binding to BMP9, another member of the 
TGF-β family [85–87]. In addition to having a single transmembrane region, endoglin has a 
constitutively phosphorylated short intracellular domain, in which a PDZ binding domain 
plays a relevant role [84, 88, 89]. In human and mouse endoglin genes, the last intron can be 
retained as a result of an alternative splicing event. This intron retention leads to the 
generation of a premature stop codon in the endoglin mRNA, which is translated into a 
shorter protein named S-endoglin [90, 91]. In humans, S-endoglin has an intracellular domain 
that is 33 residues shorter than L-endoglin and lacks the PDZ binding motif (Figure 5). One of 
the splicing factors involved in this intron retention process is serine-arginine splicing factor 
1 (SRSF1 or ASF/SF2) [92]. Notably, ASF/SF2 is also involved in the selection of the splice site 
that yields proangiogenic VEGF isoforms, a process that is inhibited by TGF-β [90, 93]. 
Interestingly, S-endoglin expression is induced during senescence in ECs [93–95] and 
macrophages [96]. It is interesting that post-ischemic reperfusion is impaired in 
 12 
senescent individuals [67]. Different cell properties observed upon L-endoglin or S-endoglin 
expression suggest that the intracellular domain is essential for the modulation of several 
cellular processes [95, 97]. Notably, it can be postulated that there should be no differences in 
those events that are mediated or promoted by the extracellular domain of endoglin between 
isoforms because this domain is identical in both protein variants. Unless stated otherwise in 
this review, the reported endoglin data correspond to the predominant isoform L-endoglin. 
A soluble form of endoglin, sEng, is released upon metalloprotease cleavage of any of the 
membrane isoforms [98, 99]. Increased sEng shedding has been reported to play a role in 
vascular pathologies such as pulmonary hypertension and preeclampsia [100, 101] and in 
several cancers [102]. The involvement of sEng in modulating angiogenic processes has also 
been suggested, i.e., impaired neovascularization in preeclampsia [103]. Moreover, sEng has 
been shown to inhibit capillary tube formation in vitro and to induce vascular leakage in vivo 
[104]. More recently, sEng has been demonstrated to impair angiogenesis in vivo [86]. Among 
the mechanisms of action proposed for sEng are sequestering of angiogenic ligands such as 
TGF-β or BMPs, or blocking the binding of full-length endoglin to the receptor complex. As a 
result, TGF-β family members cannot properly bind their receptors or transduce their 
angiogenic signal. 
 
Evidence for the role of endoglin in angiogenesis and vascular remodeling 
Endoglin is upregulated in tissues undergoing angiogenesis 
Endoglin is mainly expressed in endothelium, where its gene promoter displays elevated 
activity compared with the other cell types [105]. Endoglin expression is a stronger marker of 
ECs than other markers such as VEGFR2, adhesion molecules (ICAM, PECAM, VCAM) or von 
Willebrand Factor (vWF) [106]. In addition to endothelium, endoglin is highly expressed in 
placental syncytiotrophoblasts [107] and, at lower levels, in activated blood monocytes [108], 
VSMCs [109], pericytes [110] and other different tissues, as previously reviewed [14].  
Endoglin expression is upregulated in active endothelium undergoing angiogenesis. 
Specifically, endoglin expression increases in endothelium at the angiogenic edge, where 
vessel sprouting occurs [17]. Tissue immunostaining in different studies has revealed that 
several solid tumors and leukemic bone marrow undergoing active angiogenesis, present 
strong labeling for endoglin in the endothelium of tumor vessels [15, 111–113] and weaker 
staining in non-malignant tissues. This increased expression of endoglin in the tumor 
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endothelium correlates with a higher expression level of cellular proliferation markers [114]. 
Membrane-bound endoglin levels are elevated after myocardial infarction, and the correct 
neovascularization and recovery of the infarcted zone depends on adequate endoglin 
expression [20]. Moreover, endoglin is also highly expressed in blood vessels upon vascular 
injury in humans and mice [115], after oxygen-induced angiogenesis in the retina [17, 18] and 
during pathological angiogenesis in chronic colitis [116]. 
In vitro studies have shown that human umbilical vein endothelial cells (HUVECs) with low 
levels of endoglin are mainly quiescent, whereas HUVECs with upregulated endoglin 
expression are actively proliferating cells [111].  
 
Endoglin expression modifies angiogenesis and vascular remodeling 
Endoglin null mice die around mid-gestation (E10-11.5) from defective yolk sac 
vasculogenesis and heart growth [117, 118]. The TGF-β1 and TGF-β receptors ALK1 and 
TβRII null mice also die around mid-gestation (E10-13.5) from similar vascular alterations, 
which involve not only the endothelium but also a reduction of VSMC numbers and 
recruitment to the vasculature plexus in the yolk sac and embryo [119–121].  
Hereditary hemorrhagic telangiectasia type 1 (HHT1), also known as Rendu-Osler-Weber 
syndrome, is a vascular disease caused by mutations in the endoglin gene that leads to 
endoglin haploinsufficiency. It is characterized by an impaired angiogenic process that leads 
to arteriovenous malformations (AVMs), fragile vessel walls, and pulmonary, liver and 
cerebrovascular problems due to vascular defects [122, 123]. Endoglin itself is responsible for 
endothelium integrity because an induced lack of endoglin leads to the apparition of AVMs 
when a pro-angiogenic or an inflammatory stimulus occurs in mice with endothelial-specific 
loss of endoglin (Eng-iKOe) [124, 125]. Moreover, recent evidence has demonstrated that 
endoglin deficiency inhibits shear fluid stress blockage of EC proliferation together with 
pericyte recruitment [76]. 
Endoglin heterozygous (Eng+/-) mice –which have endoglin protein levels that are reduced by 
50%- are usually used as an animal model to study HHT1 [126]. These haploinsufficient mice 
display delayed reperfusion and impaired angiogenesis following hind limb ischemia induced 
by femoral ligation [19]. Moreover, the tumor growth rate and tumor capillary density are 
reduced in Eng+/- compared with wild-type mice [21]. Furthermore, Jerkic et al demonstrated 
that mouse aortic endothelial cells (MAECs) from these mice showed reduced VEGF 
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production and decreased proliferation and migration rates, which are essential processes for 
sprouting and initial steps of angiogenesis [19]. Another study showed that Eng+/- mice 
display impaired revascularization after myocardial infarction [20]. In addition, Eng+/- mice 
develop smaller collateral arteries in response to shear stress after hind limb ischemia, 
whereas the angiogenic response to ischemia-related hypoxia generates larger but dysplastic 
capillaries in these mice. These two effects explain the delayed blood flow recovery after 
induction of hind limb ischemia [22]. Retinal neovascularization in Eng+/- mice after oxygen-
induced ischemic retinopathy (OIR) revealed markedly impaired angiogenesis in the retina, 
with little or no angiogenic tuft formation [18]. However, a larger number of proliferative cells 
have been reported within the vasculature of normal retinas from Eng+/- mice at different 
stages of development, as compared with wild type mice. It has also been reported that 
retinas from Eng+/- pups under normal conditions show enhanced branching during sprouting 
[127], suggesting that increased proliferation does not always lead to increased effective 
angiogenesis.  
In vitro studies of the effect of different levels of endoglin in EC proliferation have produced 
discordant results. Some studies have reported that a lack of endoglin increases the 
proliferative response of ECs in culture [128–130]. Moreover, treatment with endoglin 
antisense oligonucleotides leads to reduced protein levels and an enhanced antiproliferative 
response to TGF-β [131]. At variance with these results, cultured Eng+/- ECs present smaller 
growth rates than Eng+/+ ECs [19, 132], suggesting a pro-proliferative effect of endoglin. 
Moreover, an opposite endoglin-mediated cell responses to TGF-β, such as Smad activation 
and proliferative and migratory activities, has also been reported in different biological 
settings [12, 83, 132–136]. The different results observed among these reports can be 
explained by the distinct cell types (established EC lines, primary cultures of ECs, ECs from 
veins or arteries, ECs from micro or macrovascular endothelium), cell differentiation stages 
(from embryos or adults) and experimental conditions (different media and variable TGF-β 
concentrations) used in every study. For example, experimental evidence supports the ability 
of endoglin to modulate TGF-β1 signaling in endothelium and, subsequently, angiogenesis. 
TGF-β1 has been largely considered to have an anti-proliferative effect over ECs [137], while a 
dose-dependent effect of TGF-β1 in angiogenesis and cell proliferation has also been 
described in several reports [138–140]. When endoglin expression is blocked in HUVECs, in 
vitro EC tube formation upon TGF-β1 stimulation is impaired [131]. By contrast, other studies 
have suggested that endoglin counteracts TGF-β1-induced inhibition of angiogenesis-related 
responses in vitro. Thus, endoglin has been considered to promote EC proliferation in 
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several studies. Furthermore, endoglin counteracts the inhibition of EC proliferation caused 
by high doses of TGF-β, while it promotes proliferation induced by low doses of TGF-β. This 
pro-proliferative effect of endoglin appears to be mediated by the TGF-β/ALK1/ALK5 
signaling pathway, whereas the loss of endoglin leads to TGF-β signaling through the ALK5 
pathway, which has an antiproliferative effect because ALK5 knock-down rescues EC 
proliferation in the absence of endoglin [140]. In a rat myoblast model, TGF-β showed an 
antiproliferative effect both at low and high doses, and the effect at lower doses was rescued 
by overexpression of endoglin [139]. Conversely, low doses of TGF-β have shown an endoglin-
mediated antiproliferative effect in ECs isolated from the retina, as this effect was abrogated 
in ECs from Eng+/- retinas [18]. These divergent results could again be explained based on the 
different types of cells used and their different origins. This conclusion prompts the necessity 
for further studies to elucidate the physiological role of TGF-β in EC proliferation and 
angiogenesis, as well as the function of endoglin in modulating this process.  
Moreover, BMPs, which belong to TGF-β cytokine family, are also involved in the regulation of 
angiogenesis. BMP2, 4, 6 and 7 have been reported to increase VEGF levels, to enhance 
capillary tube formation, to promote the proliferation and migration of ECs during the 
activation phase of angiogenesis, and to regulate the physiology of mural cells during the 
maturation phase [141, 142]. In contrast, antiangiogenic responses have also been reported in 
other studies, again depending on the BMP dose and cellular context [143, 144]. Contradictory 
results regarding BMP9 and BMP10 in angiogenesis have also been described. Although an 
antiangiogenic effect of BMP9 was first described [145–147], it has been accepted that it 
occurs as a consequence of high BMP9 doses, while lower doses promote angiogenesis via 
ALK1 signaling [148, 149]. Additionally, endoglin interacts with BMP2 and BMP7 when other 
members of the receptor complex are present, and it can bind to BMP9 on its own [86, 87, 
150]. Thus, endoglin may play a role in BMP signaling during angiogenesis. In support of this 
view, endoglin is necessary for BMP9 signaling in ECs involved in angiogenesis [151], and the 
blockade of BMP9 binding to ALK1 prevents endoglin binding to ALK1 and the subsequent 
angiogenic response [149]. 
Therefore, based on the current literature, endoglin appears to be an essential modulator of 
the cellular response to TGF-β and BMP cytokines. Moreover, its potential therapeutic 
implications have recently been reviewed by Jonker [152]. 
 
How does endoglin orchestrate reperfusion?  
 16 
Although it is widely recognized that endoglin is needed for proper reperfusion responses, the 
questions of where and how endoglin function to coordinate these complex responses remain 
to be answered. In this review, we intend to provide evidence of the involvement of endoglin 
in several angiogenic processes, which may help us understand why endoglin is crucial for 
accurate reperfusion. A summary of this evidence is listed in Table 1. 
 
Endoglin is involved in the response to hypoxia 
Both TGF-β1 and endoglin genes can be regulated by hypoxia due to the presence of HREs in 
their gene promoters [153]. HREs are composite regulatory elements comprising a conserved 
HIF-binding sequence and a highly variable flanking sequence that modulates the 
transcriptional response. Thus, endoglin expression is upregulated under hypoxia conditions 
in human ECs, monocytic cell lines and epithelial cells [83, 153]. Furthermore, TGF-β1 itself 
increases endoglin expression [105, 133, 153–157]. These results suggest that gene 
expression of endoglin can be regulated by a synergistic cooperation between hypoxia and 
TGF-β1 due to the presence of HREs and Smad binding motifs in its gene promoter region.  
In addition, TGF-β1 treatment further increases HIF-1α expression in endothelial cells under 
both hypoxic and normoxic conditions. TGF-β1 does not increase HIF-1α mRNA levels nor 
decrease the rate of protein degradation, suggesting that it enhances normoxic HIF-1α 
translation [158]. However, hypoxia can also induce endoglin expression via other 
mechanisms, including MAP kinase pathway activation [159]. It should be noted that in the 
presence of both hypoxia and TGF-β, endoglin is able to prevent EC apoptotic death [155].  
As described above, reduced retinal neovascularization has recently been reported in Eng+/- 
mice after OIR due to an impaired angiogenic response of ECs [18]. However, endoglin can 
function as a protective factor against endothelial apoptosis because endoglin inhibition 
enhances hypoxia and TGF-β-induced endothelial apoptosis [155]. Therefore, the expression 
of endoglin increases after hypoxia, and endoglin seems to be essential to modulate 
angiogenesis in response to this hypoxic environment. 
 
Endoglin modulates the production of angiogenic soluble factors 
VEGF and NO are two main endothelial factors that are directly involved in angiogenesis and 
vascular remodeling. There are several lines of experimental evidence indicating that NO is a 
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key component of the functional regulation of VEGF in the endothelium. NO mediates VEGF-
induced HUVEC proliferation and tube organization of ECs in 3D culture. Moreover, EC 
exposure to VEGF increases both the endothelial NO synthase (eNOS) levels and NO 
production, whereas inhibitors of eNOS reduce VEGF-induced angiogenesis [160]. 
Furthermore, NO production is directly regulated by oxygen tension and is impaired under 
hypoxic conditions, and, in turn, NO induces HIF-1α degradation [161]. Interestingly, both NO 
and VEGF have been related to the function of endoglin. 
Our group has previously demonstrated that endoglin haploinsufficiency impairs NO 
production [162] due to reduced eNOS expression [19]. These results have been confirmed 
more recently in ECs from Eng+/- mouse retina [18]. Furthermore, eNOS expression is 
upregulated by endoglin via Smad2 signaling [163]. More recently, reduced levels of eNOS 
have been described in EPCs from HHT patients [164]. Both, endoglin and eNOS proteins co-
localize and interact with one another within caveolae. Endoglin increases eNOS stability and 
is necessary for eNOS binding to its cofactor Hsp90. Therefore, eNOS is uncoupled in Eng+/- 
cells and leads to increased ROS release and decreased NO production [165]. Like eNOS, Cav-1 
and Hsp90, which can associate with endoglin, are located on the cytosolic side of plasma 
membrane, and it could be argued that their interaction with endoglin occurs through its 
intracellular domain. Consequently, this cytoplasmic interaction can be predicted to be 
altered or even abrogated in the case of the minor S-endoglin isoform. 
A link between endoglin expression and VEGF-induced angiogenesis has been reported, 
although the underlying mechanisms have not been fully elucidated. Aortic ECs isolated from 
Eng+/- mice produce less VEGF than control cells [19], whereas retinal ECs isolated from these 
haploinsufficient mice produce larger amounts of VEGF [18]. These differences can be 
explained by the different origin of the ECs: macro versus microvasculature. Moreover, HHT1 
patients, with mutations in the endoglin gene and vascular defects present increased VEGF 
plasma levels [166, 167]. BMP9 has been shown to enhance endoglin expression together 
with the blockade of VEGF-induced angiogenesis ex vivo [146]. Conversely, it has been shown 
that endoglin is required for VEGF-induced angiogenesis, although endoglin deficiency does 
not affect VEGF signaling [168]. However, anti-VEGF treatment in pancreatic carcinoma 
induces an increase in HIF-1α and in endoglin expression [169]. Moreover, endoglin and VEGF 
may be involved in endothelium stability, as will be discussed below. 
In summary, endoglin, NO and VEGF, all of which have proangiogenic activity, are in 
equilibrium because their levels are mutually regulated and their mechanisms of action are 
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interconnected. Further studies are required to fully understand the relationship among 
endoglin, NO and VEGF. 
 
Endoglin in the recruitment and differentiation of endothelial progenitors 
Populations of bone marrow-derived EPCs are present in the adult and are mobilized into the 
circulation by stimuli such as estrogen and VEGF [170]. Two populations have been 
differentially characterized from circulating endothelial precursors. On the one hand, early 
EPCs exhibit a hematopoietic profile, with a genomic fingerprint that resembles monocytes. 
On the other hand, blood outgrowth endothelial cells (BOECs), also known as endothelial 
colony forming cells (ECPCs) are considered late EPCs and present an endothelial-like 
genomic profile. BOECs have been grown in vitro in several works to study angiogenesis 
because they possess the ability to form angiogenic sprouts in vitro [171–174]. Moreover, a 
fraction of ECs within the vascular wall are the so-called “resident precursor cells” [175]. EPCs, 
both circulating and resident, can then differentiate into mature ECs that line the lumen of 
blood vessels and/or release growth factors that act in a paracrine manner to support the 
endothelium. EPCs are thus thought to function in angiogenesis and as a reservoir for the 
replacement of dysfunctional or senescent ECs to maintain the existing vessel walls [176, 177]. 
In addition, the levels of circulating EPCs are increased after vascular insult and, in several 
diseases, related to post-injury regeneration of the vasculature [178–181].  
Endoglin is considered to be expressed only by mature ECs [175, 182], but it can be expressed 
by EPCs after VEGF-driven differentiation into ECs [183]. Investigations of vasculogenesis –or 
vascularization of the embryo- in Eng+/- mice have revealed enhanced ectopic CD34 
expression in embryo cardinal veins. Because CD34 is considered to be an arterial marker, 
this finding suggests a loss of vessel identity due to deficient precursor cell homing in mice 
that are heterozygous for endoglin [184]. Characterization of BOECs from HHT1 patients has 
revealed an altered morphology, a disorganized F-actin cytoskeleton, a decreased capacity to 
form capillary-like structures and, therefore, a reduced angiogenic potential [185]. BOECs 
from HHT-1 patients showed a downregulation of the expression of genes involved in 
angiogenesis, cell adhesion, cytoskeleton, migration, and cell cycle and survival, such as WASL, 
eNOS, PCDH12 (VE-cadherin 2), PECAM-1, ANGPT-2, CCNB2 (cyclin B2), and CDC25B (cell 
division cycle 25B). In addition, these cells presented reduced adhesion, migration and 
proliferation [186]. Recently, a reduced ability of these circulating HHT1 cells to differentiate 
has been reported, revealing a reduced binding to lectin or acLDL, characteristics of mature 
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ECs, and an attenuated mobilization towards strong angiogenic stimuli such as VEGF or 
CXCL12 [164]. Taken together, these results suggest a compromised function of EPCs in 
angiogenesis in the presence of reduced cellular levels of endoglin. 
 
Endoglin modulation of endothelial cell barrier integrity  
VEGF is a major inducer of angiogenesis and increased vascular permeability, leading to 
increased vessel leakage [187, 188]. Interestingly, endoglin haploinsufficiency in Eng+/- mice 
is associated with weakness of the endothelial barrier and with an increased metastatic rate 
when tumors are produced in these mice [16]. Such increased vascular permeability was also 
observed in the distal colon of Eng+/- mice and was related to enhanced levels of VEGF [189]. 
Of note, high levels of VEGF production have also been observed in ECs isolated from Eng+/- 
mouse retinas [18]. Recently, vascular permeability, measured by the passage of fluorescent 
dextran through EC monolayers, was shown to be increased in Eng-/- and Eng+/- ECs compared 
with control ECs. This hyperpermeability of endoglin-deficient EC monolayers is associated 
with a decrease in VE-cadherin expression and constitutive activation of RhoA, and it was 
further increased by TGF-β1 or VEGF [190]. In this context, the potential involvement of VE-
cadherin deserves further analysis.  
VE-cadherin expression is related to a quiescent state of the endothelium, when stable cell-
cell interactions or adherens junctions are firmly established. VE-cadherin exerts not only a 
structural function by joining cells through homotypic interactions, but it also inhibits 
angiogenic responses such as VEGFR2 phosphorylation and signaling, thus blocking the VEGF 
proliferative signal in the endothelium [191]. Conversely, VEGF can induce VE-cadherin 
internalization and subsequent disruption of cell-cell interactions of ECs in a β-arrestin-
dependent manner [192], a process that can be modulated by endoglin due to its ability to 
interact with both VE-cadherin and β-arrestin, as well as the above described involvement in 
some responses to VEGF. Furthermore, endoglin haploinsufficiency diminishes cell-cell 
junctions by downregulating VE-cadherin, as well as PECAM, β-catenin and ZO-1 expression. 
Interestingly, VE-cadherin improves TGF-β receptor complex assembly at cell-cell contacts by 
interacting with TβRII, TβRI (ALK1 and ALK5) and endoglin. Although the interaction 
between VE-cadherin and endoglin is not necessary for the formation of the TGF-β receptor 
complex, it may act as a modulator of membrane protein assembly and the downstream signal 
transduction [18]. The same authors also reported that TGF-β-induced Smad2/3 activation in 
endoglin-deficient ECs is more persistent than Smad1 phosphorylation, in agreement with a 
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previous report [193], due, at least in part, to the VE-cadherin-related effect. Moreover, VE-
cadherin null cells present a lack of TGF-β inhibition of proliferation [194]. 
 
Endoglin regulation of focal adhesions during EC migration 
Endoglin localizes at focal adhesions and regulates cell migration [195] due, at least in part, to 
its capacity to bind zyxin, a protein that is concentrated at these zones and along the actin 
cytoskeleton [196]. Moreover, the presence of endoglin promotes the change in localization of 
zyxin related protein 1 (ZRP-1) from focal adhesions to actin fibrillar structures, which 
participates in reshaping the actin cytoskeleton [197]. Therefore, a reduction or increase in 
endoglin levels can lead to alterations in cellular morphology and cell motility. Because of the 
cytoplasmic localization of zyxin and ZRP-1, the intracellular domain of endoglin emerges as a 
key modulator of cytoskeletal organization and cell migration.  
In support of this view, BOECs from HHT1 patients exhibit an altered morphology together 
with F-actin cytoskeleton disorganization and reduced migration [185, 186]. More recently, 
studies of cultured EPCs from HHT1 patients revealed an impaired mobilization of these cells 
towards proangiogenic stimuli such as VEGF and CXCL12, as compared with cells from 
healthy donors [164]. Furthermore, endoglin neutralization with the monoclonal antibody 
TRC105 decreases HUVEC migration and capillary-like structure formation, most likely by 
inhibiting the BMP9-Smad1/5/8 signaling pathway [198]. In contrast, overexpression of 
endoglin in various non-endothelial cell types causes diminished migration rates [196]. 
Moreover, either L-endoglin or S-endoglin isoform overexpression in prostate cancer cells 
results in reduced migration [195]. This effect has been confirmed in endoglin null murine 
embryonic endothelial cells (MEECs), resulting in increased migration, whereas the rescue of 
endoglin expression reduced migration to rates similar to those of wild type cells. This effect 
on EC migration is dependent on the phosphorylation of Ser646 in endoglin by ALK5 [193, 199].  
 
Endoglin modulation of TGF-β signaling in angiogenesis  
TGF-β1 initiates signaling in ECs first by ligand binding to TβRII, which triggers the 
recruitment of TβRI and either ALK5 or the predominantly endothelial ALK1. Both TβRI and 
TβRII dimerize prior to assembly into the TGF-β receptor complex, forming not only 
homodimers but also heterodimers. It is widely accepted that stimulation of the TβRII/ALK5 
signaling complex subsequently activates the phosphorylation of Smad2/3. Once 
 21 
phosphorylated, Smad2/3 binds to Smad4, and this heteromeric complex translocates into the 
nucleus where it functions as a transcription factor, increasing the expression of the ECM 
components, PAI-1 and PDGF-B, among other genes, while inhibiting the proliferation and 
migration of ECs [200]. In addition, there is another TGF-β signaling route that involves the 
TβRII/ALK1 complex to promote the phosphorylation of Smad1/5/8. In turn, phosphorylated 
Smad1/5/8 binds to Smad4 and the resulting complex, with proangiogenic transcriptional 
activity, and promotes endothelial proliferation and migration as well as ECM degradation. 
Furthermore, the Smad1/5/8 pathway negatively regulates the expression of PAI-1, an ALK5 
target gene [193, 201–205]. This dual and opposite effect of ALK1/ALK5 remains 
controversial. For example, TGF-β signaling inhibition decreases retinal perfusion and impairs 
endothelial barrier function in mice [206], while other authors have reported a TGF-β-
mediated inhibition of proangiogenic molecules [207] or a proangiogenic effect of TGF-β 
blockade [208]. Moreover, Smad1/5/8-mediated blockade of EC migration [209], and the 
inhibition of tip cell differentiation –with a migratory phenotype– by BMP9 signaling through 
ALK1-Smad1/5/8 have been described [40]. We should take into account, as discussed above, 
that different TGF-β concentrations may exert opposite effects on ECs, further complicating 
the dissection of the precise effect of endoglin.  
Endoglin binds to TβRI (ALK1 or ALK5) and TβRII through both its extracellular and cytosolic 
domains in a ligand dependent manner, and the latter is phosphorylated by both type I and II 
TGF-β receptors [210]. The cytosolic domain of endoglin is phosphorylated at Ser634 and 
Ser635 residues by TβRII. Absence of the PDZ domain promotes this phosphorylation, 
suggesting that proteins that bind to the PDZ domain, usually scaffolding molecules, can 
interfere with endoglin phosphorylation when bound to its PDZ domain. Moreover, ALK1 
phosphorylates endoglin at Thr640 and Thr654 residues, but this process requires previous 
Ser634 and Ser635 endoglin phosphorylation. Neither and Ser635 nor the PDZ domain interfere 
with the interaction of endoglin interaction with TβRII, ALK1 or ALK5 receptors [89]. The 
cytosolic domain of endoglin is also phosphorylated by ALK5 in Ser646 and Ser649, and the loss 
of this phosphorylation impairs ALK1-induced phosphorylation of endoglin, shedding light on 
the mechanism responsible for ALK5-dependent ALK1/endoglin signaling [202, 211]. 
Moreover, the absence of cytosolic Thr residues in an endoglin mutant protein prevents 
endoglin modulation of ALK1-dependent responses, such as a reduced viability or loss of focal 
adhesion and adhesive capacity responses in HUVECs [89]. These studies suggest that it is not 
only the interaction of endoglin with the TGF-β receptor complex that modulates the effects of 
TGF-β but also the phosphorylation of its intracellular domain. The cytosolic domain 
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of endoglin has been shown to interact with several anchoring proteins, including zyxin, ZRP1, 
β-arrestin or GIPC. These interactions modulate several processes that are involved in 
angiogenesis [197, 212, 213]. S-endoglin lacks the PDZ binding motif as well as the Ser634, 
Ser635, Ser646, Ser649, Thr640 and Thr654 residues that are susceptible to phosphorylation [88] 
(Figure 5). Thus, a differential effect between L-endoglin and S-endoglin is expected, at least 
in those processes involving the cytosolic domain. 
The ability of endoglin to modulate TGF-β family signaling through the ALK1/Smad1/5/8 
pathway and its therapeutic relevance has recently been reviewed [152, 214]. It has been 
proposed that endoglin collaborates with the ALK1 signaling pathway to stimulate the active 
phases of angiogenesis through Smad1/5/8 activity [193, 215]. However, endoglin deficiency 
in the endothelium has been shown to reduce the activation not only of Smad1/5 but also of 
Smad2/3, an effect that is likely due to the reduced levels of TβRII [18].  
Furthermore, endoglin is believed to promote ALK1-mediated signaling in the presence of 
BMPs. Both BMP9 and BMP10 have been proposed to have a redundant effect in adult 
endothelium, and both cytokines can bind to ALK1 with high affinity. Unlike TGF-β, BMP9 
binds to the endoglin orphan domain by itself [87]. BMP9 signals through the endoglin/ALK1 
complex, and anti-ALK1 antibodies prevent the formation of the BMP9/ALK1/endoglin 
complexes and attenuate BMP9-dependent signaling and sprouting [149]. Additionally, 
endoglin appears to be necessary for BMP9 signaling through ALK1 in HUVECs, in which TGF-
β is unable to activate Smad1/5/8 signaling on its own [151]. Similarly, contradictory findings 
regarding the effect of BMPs in angiogenesis have been reported. On the one hand, BMP9 
signaling via the ALK1-Smad1/5/8 pathway may promote in vitro angiogenesis in human 
microvascular endothelial cells (HMVECs) and HUVECs. On the other hand, other authors have 
reported that BMP9, despite signaling via ALK1/endoglin activation, inhibits EC proliferation 
and migration, promoting the resolution phases of angiogenesis. This duality of the angiogenic 
effects of BMP9 has been thoroughly reviewed [143, 152].  
The vast majority of articles concerning to the role of endoglin in TGF-β signaling have 
assessed L-endoglin. To date, the role of the S-endoglin isoform in TGF-β/BMP signaling in 
ECs and in angiogenesis has been poorly addressed. S-endoglin and L-endoglin differentially 
modulate the ALK5 and ALK1 signaling pathways [95, 97], suggesting that they may 
contribute to the complex and dual role of TGF-β in angiogenesis. Transgenic mice that 
specifically overexpress human S-endoglin in the endothelium exhibit a deficient angiogenic 
phenotype that drives a significant delay in tumor growth [91], similar to the effects observed 
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in mice lacking L-endoglin [21, 216]. S-endoglin has been shown to promote TGF-β signaling 
through ALK5, the reporter activity of which is inhibited by TGF-β in response to L-endoglin 
expression [95]. Because endoglin is not able to bind to TGF-β by itself, requiring the presence 
of TβRII [139], the effect of S-endoglin on the TGF-β signaling may be related to receptor 
complex sequestering in competition with the long isoform. However, due to the ability of the 
extracellular domain of endoglin to bind BMP9 on its own, both L and S-endoglin are expected 
to bind similarly this ligand. Therefore, S-endoglin can sequester not only the complex but 
also the ligand in the case of BMP9. In this regard, the importance of the L-endoglin/S-
endoglin ratio based on a competitive effect between both isoforms for binding to the 
receptor complex can be postulated. According to this model, overexpression of S-endoglin 
would decrease the number of L-L endoglin homodimers and increase the frequency of L-S 
heterodimers, thus changing TGF-β signaling from ALK1/Smad1/5/8 to ALK5/Smad2/3. 
Furthermore, while L-endoglin overexpression decreases collagen I and CTGF expression and 
increases cell proliferation, S-endoglin overexpression strongly enhances collagen I and CTGF 
expression and reduces proliferation in rat myoblasts [97]. Taken together these experiments 
suggest that in contrast to the proangiogenic role of L-endoglin, S-endoglin has an 
antiangiogenic effect. 
Apart from the canonical Smad signaling pathway, TGF-β family members modulate other 
pathways such as Src kinase, ERK1/2, JNK and p38 MAP kinases or the PI3K/Akt route. MAPK 
activation has been related to enhanced cell survival, migration and capillary network 
organization, together with disruption of endothelial stability and cell-cell interactions and, 
thus, vascular permeability [18, 217, 218]. Akt signaling has emerged as a key modulator of in 
vitro capillary formation by ECs. BMP9 activates PI3K in an endoglin-dependent manner 
through endoglin PDZ domains by anchoring to the scaffolding protein GIPC that binds PI3K. 
In turn, Akt activation protects ECs from apoptosis, enhancing sprouting [213]. By contrast, 
TGF-β shows the opposite effect, reducing Akt activation and therefore promoting apoptosis, 
in an endoglin-dependent manner. Therefore, deficient TGF-β signaling could explain recent 
results showing enhanced activation of Akt, ERK, JNK and p38 in Eng+/- ECs [18]. Conversely, 
endoglin expression inhibits the ERK signaling pathway [129, 219]. Moreover, endoglin-
mediated TGF-β-induced ERK inactivation depends on the interaction between the cytosolic 
domain of endoglin and β-arrestin [212, 220]. These results further suggest that the cytosolic 
domain of endoglin is essential for proper signaling of the TGF-β family of cytokines. 
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Endoglin in vascular remodeling 
As above described, some studies have examined the role of endoglin in blood flow recovery 
after tissue ischemia. We have reported impaired reperfusion and angiogenesis after femoral 
ligation in Eng+/- compared with wild type mice [19]. Seghers et al performed a similar 
experiment a few years later, and they also studied the effect of femoral ischemia on Eng+/- 
mice together with the assessment of collateral growth. Similar to our results, after induction 
of hind limb ischemia by femoral artery ligation, Eng+/- mice exhibited a significant delay in 
blood flow recovery in the ischemic hind limb compared with control mice. The analysis of 
collateral artery size revealed significantly smaller collateral arteries in Eng+/- mice. MEECs 
were cultured under conditions of flow to mimic shear stress in vitro, revealing a time-
dependent increase in endoglin mRNA expression [22]. Collateral formation is a shear stress-
induced process that is associated with an increase in endoglin expression. Because endoglin-
deficient mice present impaired collateral growth, a role for endoglin in this process can be 
hypothesized. It has recently been demonstrated that activation of endoglin under shear 
stress mediates vascular quiescence by inhibiting EC proliferation and promoting pericyte 
recruitment [76]. This interpretation is in agreement with the observation that endoglin is 
expressed by both ECs and VSMCs, as well as by fibroblasts in the perivascular stroma of 
arteries [221–223], all of which are involved in collateral growth. Interestingly, shear stress 
plays a role in the activation of ALK5/TGF-β signaling in the endothelium [224].  
It should be noted that collateral formation is not always associated with increased endoglin 
expression. For example, cerebral hypoxia triggers active remodeling of small vessels into 
larger ones, but surprisingly, hypoxia produces a marked reduction of endoglin expression in 
brain endothelial cells (BECs) within actively remodeling arterioles [225], and these 
remodeling BECs display an angiogenic switch in β1 integrins from α6 to α5, which has been 
previously described in angiogenesis [226]. In in vitro experiments, TGF-β1 promotes the 
angiogenic switch of BEC β1 integrins. Taken together, these data suggest that BECs in 
remodeling brain collaterals show reduced endoglin expression, thereby altering TGF-β1 
signaling to promote an angiogenic switch in β1 integrins, facilitating vascular remodeling and 
the formation of new arteries that increase the supply of blood to the ischemic areas [225]. 
These findings also suggest that the precise role of endoglin in vascular remodeling depends 
on the tissue in which the ischemia is produced. 
 
Endoglin regulation of mural and mononuclear cell recruitment 
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Mural cell recruitment is a key process in both arteriogenesis and collateral growth. Endoglin 
is highly expressed by ECs during arteriogenic processes at the same time as mural cell 
recruitment to vessels [227]. Several lines of experimental evidence support the involvement 
of endoglin in mural cell recruitment to EC tubes. First, mice lacking endoglin (Eng-/-) die by 
gestational day 11.5 from defective vascular development, although the vasculogenesis 
process remains unaffected [117, 118, 126]. Interestingly, loss of endoglin in these Eng-/- mice 
causes poor vascular smooth muscle development and arrested vascular remodeling [117]. It 
has also been reported that in yolk sacs from endoglin KO mice, αSMA levels are remarkably 
low because of the failure of VSMCs to differentiate and associate with ECs, so that blood 
vessels remain fragile and become dilated [117, 228]. This process is compatible with the 
characterization of HHT1 by recurrent epistaxis and internal hemorrhage due to the presence 
of immature and leaky vessels [229]. These results demonstrate that endoglin is essential for 
angiogenesis and VSMC recruitment to vessels. Failure of the endothelium to undergo 
remodeling in Eng-/- mice following arrested VSMC development suggests that VSMCs play a 
key role in regulating endothelial organization and that it is involved in the pathogenesis of 
HHT1 [28].  
Integrins play a key role in angiogenesis and vessel remodeling and maturation [54]. Thus, in 
growing vessels, the basement membrane undergoes degradation and is replaced by a 
fibronectin-rich matrix that induces integrin expression in mural cells, specifically fibronectin 
receptors such as α5β1 and αvβ3. Both integrins are involved in endothelial and mural cell 
proliferation and sprouting [230–232].  
Integrins also play a major role in monocyte recruitment, a major step in vascular remodeling 
as previously described. Thus, leukocyte arrest is mediated by the activation of integrins to 
assume their extended, high-affinity conformation, resulting in the binding of endothelial 
ligands such as ICAM-1 or VCAM-1 [233]. Human endoglin displays the prototypic RGD motif 
involved in integrin-based interactions within its ZP juxtamembrane domain [84, 85]. In 
addition, a physical and functional interplay between endoglin and β1 integrins has been 
reported [107, 196, 209, 234]. More recently, endothelial endoglin has been identified as a 
ligand for leukocyte integrins [27].   
In addition to its role in mononuclear cell recruitment, endoglin has also been involved in the 
regulation of its function. Thus, endoglin is upregulated in activated monocytes from healthy 
subjects [108], and this activation is impaired in cells from HHT1 patients [235]. In these 
patients, the type of cells composing the mononuclear cell fraction is modified. Thus, whereas 
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in healthy subjects the most predominant cell types are T lymphocytes, monocytes, and 
macrophages, with lower proportions of NK cells, dendritic cells and EPCs, the proportion of 
NK and T lymphocytes in HHT patients was found to be markedly reduced, while the B 
lymphocyte and monocyte proportions were unaltered and the phagocytic activity of the 
monocytes was conserved [236]. It has also been reported that HHT1 patients have reduced 
mononuclear cell recruitment to damaged tissue, which could explain the impaired tissue and 
vascular repair observed in these patients [237, 238]. In Eng+/− mice subjected to an 
experimental infarct, microvascularity within the infarct zone was strikingly lower than that 
in wild type mice, which resulted in a greater deterioration in cardiac function [20]. Moreover, 
after distal middle cerebral artery occlusion, Eng+/− mice showed larger infarct/atrophic 
volumes and fewer infiltrating macrophages than wild type animals, suggesting that endoglin 
deficiency impairs brain injury recovery by impairing macrophage homing, delaying 
inflammation resolution, and reducing angiogenesis [239]. Furthermore, in an experimental 
model of brain arteriovenous malformations in mice induced by local injection of the VEGF 
gene, it has been reported that, compared with control mice, Eng-deleted mice show fewer 
macrophages homed to the angiogenic area 2 weeks after angiogenic stimulation [240]. This 
phenomenon can be explained by the reduced homing of monocytes in the injured tissue in 
Eng-deficient mice, as previously reported in other models [20, 27, 239]. However, Eng+/− 
animals showed more tissue macrophages at 8 weeks the stimulus, when arteriovenous 
malformations were already formed, resulting in persistent inflammation, which can be 
explained by an impaired clearance of Eng-deficient macrophages in the injured tissue 
(angiogenic region) [239, 240]. 
Reduced infiltration of leukocytes in HHT1 patients and in Eng+/− mice can be explained by 
their reduced endoglin levels and involvement of the endoglin-integrin interaction in 
leukocyte recruitment [27, 241]. However, the previously described effects do not seem to be 
due only to a decrease in the number of inflammatory cells in the infarct area. A study 
conducted by van Laake et al [20], showed that mononuclear cell recruitment was similar in 
wild type and Eng+/− mice, but an impaired function of the low-endoglin mononuclear cells 
produced defects in vessel formation and heart function in Eng+/− mice. This phenotype was 
rescued by the injection of mononuclear cells from healthy human donors but not by 
mononuclear cells from HHT1 patients. This result is in agreement with the reduction in 
monocyte function (including oxidative burst and phagocytosis) in HHT patients [242] and in 
mouse monocytes lacking endoglin [243]. Moreover, a different role for endoglin isoforms in 
the regulation of monocyte-macrophage functions has been proposed because L-
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endoglin overexpression promotes a pro-inflammatory M1-like macrophage phenotype, 
whereas S-endoglin favors the expression of anti-inflammatory M2 macrophage markers [96].  
Endothelial endoglin may also interact with the integrins present in vascular mural cells. 
Because endothelial endoglin is a ligand for β1 integrins and VSMCs express these integrins 
[56], we can hypothesize that these receptors are involved in the adhesion of mural cells to 
ECs. A first candidate is α5β1, a proangiogenic integrin that is required for hypoxia-induced 
angiogenesis [232] and that is upregulated during angiogenesis and remodeling [225, 226, 
230]. Integrin α5β1 specifically recognizes the RGD motif in extracellular matrix proteins and 
is expressed by VSMCs, regulating their adhesion and recruitment to blood vessels [56]. Co-
immunoprecipitation of endoglin with the α5 integrin subunit demonstrated that endoglin 
could bind to this integrin independently of the RGD motif [209]. These authors reported that 
endoglin inhibits 1 integrin subunit lysosomal degradation, thus promoting 
fibronectin/integrin 51 complex formation, which in turn induces endoglin/ALK1 complex 
formation and enhances TGF-1 activation of the Smad1/5/8 pathway. Moreover, TGF-1 
activates 51 signaling in an endoglin-dependent manner because endoglin interacts with 
integrin via its extracellular domain to form complexes that are internalized to induce focal 
adhesion kinase (FAK) activation. A very recent study from our laboratory has demonstrated 
a critical role for endoglin in integrin-mediated adhesion of mural cells to ECs [28]. We 
describe an enhanced adhesion between vascular ECs and mural cells by integrin activators, 
which is inhibited by the suppression of membrane endoglin or β1-integrin, as well as by the 
addition of anti-integrin α5β1 antibody or a peptide containing the RGD motif. Analysis of the 
binding of adherent mural cells to cells in suspension expressing different endoglin mutants 
indicates that the endoglin RGD motif plays a major role in the adhesion process. Endoglin 
haploinsufficiency induces a pericyte-dependent increase in vascular permeability [28], 
whereas another study reported that retina from Eng+/- mice presents no differences from 
wild type mice in terms of the abundance of NG2, a protein that is characteristic of pericytes 
and VSMCs [127]. Further investigations are needed to elucidate the physiological role of 
endoglin in mural cell recruitment.  
ALK5 inhibition, together with VEGF stimuli, induces the expression of 5 and 3 integrins in 
ECs and promotes angiogenesis in vitro and in vivo [231]. Because both endoglin isoforms 
differentially regulate the ALK1/ALK5 balance, it is tempting to speculate whether they 
modulate integrin expression. In this sense, using a human promonocytic cell line, it has been 
shown that both L-endoglin and S-endoglin inhibit α1, β2, αM and αL integrin expression, as 
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well as integrin-mediated cellular adhesion and monocytic adhesion to ECs [244]. It remains 
to be established whether each endoglin isoform drives a cell lineage-dependent regulation of 
integrin expression. 
Endoglin is not only expressed in the endothelium but also in mural cells, although little is 
known about its role in these cells. It has been reported that secreted protein acidic and rich 
in cysteine (SPARC) promotes pericyte recruitment in vivo and pericyte migration in vitro by 
regulating the function of endoglin. SPARC prevents endoglin incorporation into focal 
complexes, thus promoting pericyte migration. In addition, in the presence of SPARC, endoglin 
does not bind to latent TGF-β/αν integrin complexes, whereas the absence of SPARC allows 
endoglin to recruit TGF-β receptor components to latent TGF-β/αν integrin complexes. This 
process promotes ALK5/Smad2 signaling, which, in turn, blocks pericyte migration and 
recruitment [110]. Mesoangioblasts (MABs) are vessel-associated stem cells that express 
pericyte markers and improve skeletal muscle regeneration. Recently, the Smad1/5/8 
pathway has been shown to be involved in MAB myogenic differentiation, but there are still 
no clues for the potential role of endoglin in this process. [245]. 
 
CONCLUSIONS AND PERSPECTIVES 
Blood vessel formation and remodeling are essential processes in the maintenance of tissue 
homeostasis and function, and therefore their alteration causes a variety of pathologic 
conditions. Endoglin, a TGF-β family co-receptor that is expressed mainly in endothelium, 
plays a key role in angiogenesis and blood vessel homeostasis, becoming a potential 
therapeutic target for pro- and antiangiogenic approaches for the treatment of diseases such 
as cancer, diabetes complications or post-ischemic disease. Endoglin expression is increased 
in the active endothelium, and it has been related to several endothelial processes involved in 
angiogenesis and vessel remodeling such as EC proliferation and migration, ECM production, 
leukocyte extravasation or endothelial interactions with mural cells. 
TRC105 monoclonal antibody against endoglin acts as an anticancer drug that reduces tumor 
angiogenesis and is already used for the treatment of many solid tumors with satisfactory 
results. However, apart from this application, the endoglin facet as a therapeutic target for 
angiogenesis modulation has not been further exploited, due, at least in part, to the lack of 
knowledge regarding the precise role of endoglin during angiogenesis. 
Unpublished studies from our laboratory reveal that post-ischemic angiogenesis is not 
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improved in transgenic mice overexpressing the main isoform of endoglin (Nuñez-Gomez, 
Pericacho, Ollauri-Ibañez and Lopez-Novoa unpublished observations). It should be noted 
that, under normal conditions, endoglin expression is increased in response to ischemia, and 
thus it is likely that the endoglin present in the vessels of ischemic tissues in wild type mice is 
sufficient for producing the maximal angiogenic response and that endoglin does not improve 
the process. However, an excess of full-length exogenous endoglin could be useful in 
situations in which revascularization is reduced, as observed in patients with advanced age, 
hypercholesterolemia or diabetes [246]. It should be noted that under these conditions, NO 
production, a critical mediator of angiogenesis and revascularization, is reduced, and lower 
levels of endoglin are associated with lower NO production [19, 162, 247], thus providing 
additional support for the hypothesis that endoglin is reduced in these diseases and that the 
administration of vectors containing endoglin could improve post-ischemic angiogenesis in 
these situations.  
Finally, better knowledge of the mechanisms by which endoglin regulates post-ischemic 
vascularization could allow the development of effective therapies for diseases in which these 
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Hypoxia is the main angiogenic stimulus. a. High levels of HIF-1 accumulated in hypoxia 
due to the lack of its degradation stimulate the expression of genes with a hypoxia response 
element (HRE) in their promoters, such as VEGF, TGF-β or endoglin. Adapted from Lee et al, 
2004 [31] and Gray et al, 2005 [34]. b. The hypoxic environment stimulates HIF-1 
accumulation and the subsequent generation of a VEGF gradient between hypoxic tissue and 
nearby vessels where VEGF stimulates sprouting and new vessel growth. 
 
Figure 2. 
Overview of the mechanism of angiogenesis and arteriogenesis. a. VEGF signaling 
through VEGF receptor type 2 (VEGFR-2) induces endothelial cell differentiation into a "tip" 
phenotype. Tip cells modulate the function of contiguous “stalk” by a mechanism mediated by 
the Notch-Dll4 and other signaling pathways. In the presence of high levels of membrane 
endoglin, tip cells degrade the ECM and migrate towards the hypoxic focus guided by the 
VEGF gradient, whereas stalk cells follow tip cells and proliferate, generating the early new 
vessel. Adapted from Blanco and Gerhardt, 2013 [39] and Larrivee et al, 2012 [40]). b. Shear 
stress trigger several endothelial processes during arteriogenesis, including EC release of NO 
and MCP-1, which mediate vasodilation and recruitment of mononuclear cells, respectively, 
together with endothelial quiescence and the recruitment of mural cells. Adapted from 
Carmeliet, 2000 [7], van Varik et al, 2012 [9] and Deindl et al, 2013 [68]. 
 
Figure 3.  
Relationship among HIF, endoglin, VEGF and FGF in the endothelium. HIF-1 
accumulation during hypoxia induces the expression of endoglin and VEGF genes under HRE 
control. There is an interrelationship between endoglin, VEGF and FGF because VEGF itself 
induces endoglin expression, and FGFR2 and FGF induces VEGF expression. The endoglin, 
VEGF and VEGF/FGF pathways promote endothelial proangiogenic responses. Adapted from 






Figure 4.  
Structure of the intracellular domain of endoglin membrane isoforms, L-endoglin and 
S-endoglin. Structure and peptide sequence of the endoglin cytosolic domain. Several Ser and 
Thr residues within the intracellular domain of endoglin are susceptible to phosphorylation 
by TβRII, ALK1 and ALK5 receptors and also by other kinases such as Src or PKC. Adapted 
from Pérez-Gómez et al, 2005 [91], Koleva et al, 2006 [89] and Pan et al, 2014 [130]. 
 
Figure 5. 
Role of endoglin in TGF-β family signaling in endothelium. Endoglin mediates TGF-β and 
BMP9 signaling though the ALK1 and Smad1/5/8 pathway, leading to an active phenotype of 
endothelium, with increased proliferation and migration and a role in ECM degradation. This 
pathway antagonizes the ALK5 and Smad2/3 route involved in endothelial quiescence, ECM 
deposition mediated by PAI-1 and other cytoquines and mural cell recruitment. Adapted from 
ten Dijke et al, 2008 [12] and Bernabeu et al, 2009 [132]. 
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TABLE 1. Endoglin levels and vascular events 
 
 
Effects of reduced levels of endoglin 
Delayed reperfusion and altered vascularization following hindlimb ischemia [19, 
22]. 
Reduced tumor growth rate and tumor capillary density [21]. 
Impaired revascularization after myocardial infarction [20]. 
Defects in vessel maturation and mural cell recruitment [28, 117, 227, 228]. 
Reduced VEGF production by macrovascular ECs [19]. 
Increased VEGF production by microvascular ECs or angiogenic tissue [18, 188]. 
Reduced EC proliferation and/or migration rates [19, 139, 163, 184, 185]. 
Increased EC proliferation and/or migration rates [128–130]. 
Impaired EC sprouting in response to VEGF [167]. 
Increased endothelial permeability and/or metastasis [16, 18, 188, 189]. 
Altered EPC differentiation and recruitment [163, 183–185] 
Circumstances associated to increased endoglin expression 
Cardiac and vascular injury [20, 115]. 
Oxygen-induced angiogenesis in the normal retina [17, 18]. 
Pathological angiogenesis in chronic colitis [116]. 
Tumor vascularization [15, 16, 112, 114] 
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